Yacine Amrani, PhD

Senior Principal, New York

Yacine brings 8+ years of life sciences consulting expertise to Deallus. He has extensive experience in helping large and small pharma and biotech companies assess opportunities for assets in development. He also is well versed in life cycle management, conducting due diligence for licensing acquisitions, developing evidence generation plans and value communication strategies for market access, and using primary research and analytic tools to assess payer decisions. His previous experience as a pharmacist and research scientist, coupled with his business acumen, enables Yacine to provide clients with insights that allow them to push their portfolio pipelines forward.

What do you consider your strengths?

I have had the chance throughout my training and career to learn from some of the very best in the world, whether during my immunology and cancer research (my head of department at MSKCC was Jim Allison – Nobel Prize laureate, one of the founding fathers of Immmuno-Oncology) or after switching to consulting and working at two of the most renowned Pharma/Biotech strategic consulting firms in the world. This sets very strong foundations to expand our work to address complex, yet fascinating business challenges in the field of value development, pricing, and market access strategy.

What do you bring to Deallus and clients that is unique?

An ability to speak the pricing, reimbursement, market access, pricing, forecasting language of the commercial teams (e.g., price, reimbursement, launch sequence by indication/geography) and that of their medical and R&D colleagues (e.g., evidence generation, significance of clinical results, length of trials, endpoints). Add to that a breadth of experience in the field of US, but also Global reimbursement and pricing, where complex policies and rules shape commercial and R&D strategic decisions. The challenges and pressures are growing out there. No market is insulated; our clients have to think globally while acting locally, working hand in hand to ensure common growth and success. I can help them do that.

Yacine Amrani Deallus Senior Principal New York

Background and experience

  • 8+ years in life sciences consulting

  • Strong experience in life cycle management and asset acquisition

Therapy area expertise

  • Oncology

  • Cardiology

  • Ophthalmology

  • Immuno-inflammation

  • Gene therapy

  • Pain therapy

  • Alzheimer disease

  • Metabolic diseases

Deallus New York

Authored insight

CARe To Understand What Will Shape CAR T’s Future?

CAR T-cell therapies space is complex, highly competitive, and quickly evolving. Add the pandemic to the mix and the logistical, reimbursement, and pricing landscape grows even more complicated. In this in-depth paper we research the current state of CAR T-cell therapies and speculate on the factors currently making the largest impact - China, Commercialization, and COVID-19. Read more for a comprehensive, well-researched take on the space.

People also viewed

We are always seeking other like-minded people who are as passionate about their work as we are, have a track record of demonstrating initiative, and are looking for a position where they can achieve their full potential.

Join us!

Join our team
Go to Top